Fosfomycin Pregnancy and Breast Feeding Warnings

Fosfomycin is also known as: Monurol

Overview

If you become pregnant, contact your doctor. You will need to discuss the benefits and risks of using Fosfomycin while you are pregnant. It is not known if Fosfomycin is found in breast milk. Do not breast-feed while taking Fosfomycin .

Fosfomycin Pregnancy Warnings

Fosfomycin has been assigned to pregnancy category B by the FDA. Animal studies have revealed evidence of fetotoxicity, but only at dosages which also resulted in maternal toxicity. Intramuscularly administered fosfomycin sodium crosses the placental barrier. There are no controlled data in human pregnancy. Fosfomycin is only recommended for use during pregnancy when benefit outweighs risk.

Fosfomycin has been shown to cross the placental barrier in humans. At dosages 1.4 and 9 times the human dose, no teratogenic effects were observed in rats. When given to rabbits at 2.7 and 9 times the human dose, fetotoxicities were observed, but maternal toxicity was also present. These toxicities are considered to be changes in intestinal microflora according to the manufacturer. Fosfomycin tromethamine 3 grams orally in water was given to 153 pregnant women with bacteriuria as a single dose. Infecting organisms were eradicated in 96% of patients, with a recurrence rate of 3% after 25 to 30 days. Minimal maternal side effects occurred and no serious adverse fetal effects were documented. The trimester in which the medication was administered was not reported.

Fosfomycin Lactation Warnings

There are no data on the excretion of fosfomycin into human milk. Excretion is expected due to its low molecular weight. The manufacturer recommends that due to the potential for serious adverse reactions in nursing infants, a decision should be made to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother. Due to the fact that fosfomycin is given in a single dose, breast-feeding should be able to be safely resumed within 36 to 48 hours after administration, although studies supporting this suggestion are not currently available.

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and Drugs.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This drug information does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information in contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.